Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter and year ended December 31, 2025. Financial Results “In 2025, our Cushing's syndrome business experienced a surge in demand due to growing recognition amon.

Business Wire • 3 hours ago

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Corcept Therapeutics Incorporated (CORT)

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northen District of California on behalf of all persons or entities who purchased or otherwise acquired Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ: CORT) securities between October 31, 2024, and December 30, 2025, inclusive (the “Class Period”).

GlobeNewsWire • 8 hours ago

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Corcept Therapeutics Incorporated to Secure Counsel Before Important Deadline in Securities Class Action – CORT

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Corcept Therapeutics Incorporated (NASDAQ: CORT) between October 31, 2024 and December 30, 2025, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 21, 2026.

GlobeNewsWire • 3 hours ago

Corcept Therapeutics (CORT) Litigation: Hagens Berman Alerts Corcept (CORT) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline

Lawsuit Alleges Corcept Ignored Repeated FDA Warnings Against Filing Relacorilant NDA; Stock Plunged 50% on Revealed "Evidence Gaps" SAN FRANCISCO, Feb. 24, 2026 /PRNewswire/ -- National shareholder rights law firm Hagens Berman is notifying investors that a securities class action lawsuit has been filed against Corcept Therapeutics Inc. (NASDAQ: CORT) and certain of its top executives. The lawsuit, Allegheny County Employees' Retirement System v.

PRNewsWire • 11 hours ago

CORT Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Corcept Therapeutics Inc.

SAN DIEGO, Feb. 24, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Corcept Therapeutics Incorporation (NASDAQ: CORT) common stock between October 31, 2024 and December 30, 2025. Corcept is a pharmaceutical company focused on the development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol.

PRNewsWire • 2 hours ago

INVESTOR DEADLINE: Corcept Therapeutics Incorporated Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces

SAN DIEGO--(BUSINESS WIRE)---- $CORT #CORT--The lawsuit alleges that defendants failed to disclose that the FDA raised concerns about the adequacy of evidence supporting relacorilant's NDA.

Business Wire • 7 hours ago

CORCEPT CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Corcept Therapeutics Incorporated and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C.  Litigation Partner  Brandon Walker  Encourages Investors Who Suffered Losses In Corcept (CORT) To Contact Him Directly To Discuss Their Options

GlobeNewsWire • Feb 23, 2026

INVESTOR ALERT: Securities Class Action Filed Against Corcept Therapeutics Incorporated – Investors Encouraged to Contact Kirby McInerney LLP

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Corcept Therapeutics Incorporated (“Corcept” or the “Company”) (NASDAQ:CORT) securities during the period of October 31, 2024 through December 30, 2025, inclusive (“the Class Period”). If you suffered a loss on your Corcept investments, you have until April 21, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff app.

Business Wire • Feb 23, 2026

Corcept Therapeutics (CORT) Litigation: Hagens Berman Alerts Corcept (CORT) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline

SAN FRANCISCO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is notifying investors that a securities class action lawsuit has been filed against Corcept Therapeutics Inc. (NASDAQ: CORT) and certain of its top executives. The lawsuit, Allegheny County Employees' Retirement System v.

GlobeNewsWire • Feb 23, 2026

INVESTOR DEADLINE: Corcept Therapeutics Incorporated Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that the Corcept class action lawsuit seeks to represent purchasers or acquirers of Corcept Therapeutics Incorporated (NASDAQ: CORT) common stock between October 31, 2024 and December 30, 2025, inclusive (the "Class Period").  Captioned Allegheny County Employees' Retirement System v.

PRNewsWire • Feb 23, 2026